Cann Group (ASX:CAN)

  • Symbol:ASX:CAN
  • Sector:Healthcare
  • Industry:Pharmaceutical
  • CEO:Peter Crock
  • Founded:2015

Cann Group (ASX:CAN) Stock Price

Cann Group (ASX:CAN) Company Overview

When it comes to the medicinal cannabis market, the Cann Group (ASX:CAN) are dedicated to breaking through the grass ceiling. The company's goal is to become the leading developer and supplier of cannabis, cannabis resin, and medicinal cannabis products in Australia.

Rather than trying to fill a specific niche like some of its competing cannabis stocks—such as targeted clinical applications or over-the-counter skincare products—Cann's team is focused on refining, supplying, and distributing cannabis.

The company favours a vertically integrated business model that handles all aspects of the cannabis market, covering everything from cultivation, clinical evaluation, and research and development, all the way down to packaging and exports.

The Cann Group was also granted the first ever Australian Medicinal Cannabis Research Licence in February 2017, and it is currently building the largest cultivation facility in the country, located in close proximity to Melbourne Airport. The state-of-the-art facility will to be over 37,000 square metres in size, with Australia Pacific Airports Melbourne contributing $100 million to the project via an unquantified lease incentive.

Cann has also secured strategic partnerships with a number of other international companies, including the Canadian marijuana giant Aurora Cannabis, the Canopy Growth Corp, and Fundacion Daya.

Cann Group (ASX:CAN) Financials

More From Cann Group...

An Investor's Guide to the Green Fund Paper Portfolio
Pot Stocks – The Bulls and Bears Week 13
CBD Pet Supplement Producers Paw for Control of Growing Market
6 Additional Aussie cannabis stocks to watch in 2019 – cannpal, botanix, thc asx and more!
4 Reasons to Invest in the Australian Cannabis Market

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Signup to get updates.


Peter Crock
Chief Executive Officer
Peter has reset the business plan as directed by the board and led the company through a successful initial public offering (IPO) to list on the Australian Securities Exchange (ASX), raising $13.5 million while bringing outstanding institutional and cornerstone investor support.
Allan McCallum
Non-Executive Chairman
Allan is Chairman of Tassal Group Ltd (ASX:TGR), Australia's largest producer of Atlantic salmon. His previous board roles include Medical Developments International Ltd (ASX:MVP), Incitec Pivot Limited (ASX:IPL) and Graincorp Limited (ASX:GNC).
Philip Jacobsen
Non-Executive Director
Philip is an experienced public company director who co-founded Premier Artists in 1975 and the Frontier Touring Company in 1979.
Doug Rathbone
Non-Director Director
Over a 40-year career at Nufarm, Doug led the transformation of a small Australian agribusiness company into one of the world's leading crop protection and seed companies with an extensive global footprint.
Geoff Pearce
Non-Executive Director
Geoff is Chairman of Probiotec Limited (ASX:PBP). He has extensive experience in areas such as manufacturing, procurement, distribution and regulatory affairs.